Bayforest Capital’s AbbVie ABBV Stock Holding History

Bayforest Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-665	Closed	-$145K	–	919
2026 Q1	$145K	Buy	+665	New	+$148K	0.16%	228

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bayforest Capital's ABBV Position: Q2 2026 in Review

Bayforest Capital sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 665 shares — an estimated $145K sold.

Bayforest Capital first reported a position in ABBV in Q1 2026 and held it in 1 quarter. The position peaked at $145K in Q1 2026. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Bayforest Capital reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Bayforest Capital sold 665 AbbVie shares in Q2 2026, an estimated $145K.
Bayforest Capital first reported a position in AbbVie in Q1 2026 and held it in 1 quarter.
Bayforest Capital's AbbVie position peaked at $145K in Q1 2026.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.